Eli Lilly disclosed Phase 3 Attain‑Maintain results showing orforglipron, a once‑daily oral GLP‑1 receptor agonist, helped patients maintain weight loss over 52 weeks after prior treatment with injectable GLP‑1 therapies. The trial met its primary and key secondary endpoints, supporting Lilly’s regulatory filing seeking approval. Lilly requested FDA clearance and received one of the agency’s new “national priority” vouchers, a status that shortens the review window to weeks rather than standard months. The data position orforglipron as a maintenance therapy and expand the oral GLP‑1 category’s commercial footprint against injectables like Wegovy and Zepbound. Regulators, payers, and clinicians will watch durability, safety, and comparative effectiveness data as the market for obesity therapies grows rapidly and reimbursement debates intensify.